Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADP-ribosylation factor-like protein 5A (ARL5A) is a member of the ARF family of small GTP-binding proteins, structurally related to ADP-ribosylation factors but lacking their enzymatic activity. ARL5A is primarily localized to the nucleus/nucleolus, interacts with HP1alpha, and is developmentally regulated. It may play a role in nuclear and nucleolar dynamics or signaling cascades during embryonic development, although its precise cellular actions remain incompletely defined. Unlike canonical ARF proteins, ARL5A lacks ADP-ribosylation activity and its direct involvement in signaling, trafficking, or disease mechanisms is still under investigation. Disease associations include mucinous stomach adenocarcinoma and Dyggve-Melchior-Clausen disease, but no drugs or pharmacological modulators are currently reported for this target[3][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADP-ribosylation factor-like protein 5A (ARL5A).